Grant: Idea to Innovation
University of Calgary
$125,000.00
Mass spec studio software for the pharmaceutical market - a phase one project
FY 2017-18
Summary
Imagine spending hundreds of thousands of dollars on powerful new technology for life science research, onlyto discover that you cannot fully use the data that it produces. This is a situation in a large number of academicand industry laboratories that have purchased mass spectrometers for R&D spanning all areas of biological andenvironmental sciences. New technologies in mass spectrometry have spurred tremendous growth in newmethods for compound characterization, especially in the biopharmaceuticals industry. Biopharmaceuticals areprotein drugs. They represent a very effective class of pharmaceutical agents and the area is experiencing ahigh rate of growth worldwide. Mass spectrometry is the perfect choice of technology to support thedevelopment of new protein drugs, and to ensure that these complicated drugs are safe to use. The companiesthat make mass spectrometers are not able to keep up with the many new directions that biopharmaceuticalcompanies are taking mass spectrometry, and the situation is expected to deteriorate further. We developed atransformative solution to this problem, in the form of an application-building software platform called theMass Spec Studio. This platform strongly reduces the development time for creating new applications. It iscurrently houses research-grade plug-ins that are very useful for a form of protein characterization calledhigher-order structure (HOS) analysis. In this project we will complete version 2 of the Mass Spec Studio. Itwill contain industry-leading plug-ins for HOS analysis and streamline the application development processeven further. The goal of the project is to create a package of technologies that will help mass spectrometrykeep pace with the needs of the biopharmaceutical industry, and ensure that protein drugs are effective andsafe.
Program
Idea to Innovation
Recipient
Location
Alberta, Canada
Recipient Type
Academia
Type
Grant
Source
NSERC's Awards Data
As published
Application id
508445-2017
Name nom
Schriemer, David
Department département
Biochemistry and Molecular Biology
Organization id
11
Institution établissement
University of Calgary
Province en
Alberta
Province fr
Alberta
Country en
CANADA
Country fr
CANADA
Fiscal year exercice financier
2017
Competition year année de concours
2017
Award amount
125000
Program id
I2IPJ
Program name en
Idea to Innovation
Program name fr
De l'idée à l'innovation
Group en
Research partnerships programs
Group fr
Programmes de partenariat
Committee code
96
Committee name en
RPP Internal Decision Cttee
Committee name fr
Cté de décision interne - PPR
Area of application code
1211
Area of application group en
Advancement of knowledge
Area of application group fr
Avancement des connaissances
Area of application en
Medical and health sciences
Area of application fr
Sciences médicales et de la santé
Research subject code
3504
Research subject group en
Analytical chemistry
Research subject group fr
Chimie analytique
Research subject en
Bioanalytical chemistry
Research subject fr
Chimie bioanalytique
Partie
1
Nb partie
1
Application title
Mass spec studio software for the pharmaceutical market - a phase one project
Keyword
NSERC
Application summary
Imagine spending hundreds of thousands of dollars on powerful new technology for life science research, onlyto discover that you cannot fully use the data that it produces. This is a situation in a large number of academicand industry laboratories that have purchased mass spectrometers for R&D spanning all areas of biological andenvironmental sciences. New technologies in mass spectrometry have spurred tremendous growth in newmethods for compound characterization, especially in the biopharmaceuticals industry. Biopharmaceuticals areprotein drugs. They represent a very effective class of pharmaceutical agents and the area is experiencing ahigh rate of growth worldwide. Mass spectrometry is the perfect choice of technology to support thedevelopment of new protein drugs, and to ensure that these complicated drugs are safe to use. The companiesthat make mass spectrometers are not able to keep up with the many new directions that biopharmaceuticalcompanies are taking mass spectrometry, and the situation is expected to deteriorate further. We developed atransformative solution to this problem, in the form of an application-building software platform called theMass Spec Studio. This platform strongly reduces the development time for creating new applications. It iscurrently houses research-grade plug-ins that are very useful for a form of protein characterization calledhigher-order structure (HOS) analysis. In this project we will complete version 2 of the Mass Spec Studio. Itwill contain industry-leading plug-ins for HOS analysis and streamline the application development processeven further. The goal of the project is to create a package of technologies that will help mass spectrometrykeep pace with the needs of the biopharmaceutical industry, and ensure that protein drugs are effective andsafe.